Literature DB >> 20389059

Indoxyl sulfate upregulates expression of ICAM-1 and MCP-1 by oxidative stress-induced NF-kappaB activation.

Zohra Tumur1, Hidehisa Shimizu, Atsushi Enomoto, Hitoshi Miyazaki, Toshimitsu Niwa.   

Abstract

BACKGROUND/AIM: Indoxyl sulfate, a uremic toxin, is considered a risk factor for cardiovascular disease (CVD) in chronic kidney disease (CKD). The present study aimed to determine whether indoxyl sulfate increases the expression of intercellular adhesion molecule-1 (ICAM-1) and monocyte chemotactic protein-1 (MCP-1) by reactive oxygen species (ROS)-induced activation of nuclear factor-kappaB (NF-kappaB) in vascular endothelial cells.
METHODS: Human umbilical vein endothelial cells (HUVEC) were incubated with indoxyl sulfate. The expression of ICAM-1 and MCP-1 in HUVEC was analyzed by quantitative reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting. Phospho-NF-kappaB p65 (Ser 536), an active form of the NF-kappaB subunit, was determined by Western blotting.
RESULTS: Indoxyl sulfate significantly increased the mRNA expression of ICAM-1 and MCP-1 in HUVEC in a time- and concentration-dependent manner. Inhibitors of NF-kappaB (ammonium pyrrolidinedithiocarbamate and isohelenin) and an antioxidant (N-acetyl-L-cysteine) suppressed the indoxyl sulfate-induced expression of ICAM-1 and MCP-1 in HUVEC. Indoxyl sulfate increased phospho- NF-kappaB p65 in HUVEC, and N-acetyl-L-cysteine suppressed it.
CONCLUSIONS: Indoxyl sulfate upregulates the expression of ICAM-1 and MCP-1 by ROS-induced activation of NF-kappaB in vascular endothelial cells. Thus, indoxyl sulfate may play an important role in the development of CVD in CKD by increasing the endothelial expression of ICAM-1 and MCP-1. 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20389059     DOI: 10.1159/000299798

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  83 in total

1.  Effect of uraemia on endothelial cell damage is mediated by the integrin linked kinase pathway.

Authors:  Andrea García-Jérez; Alicia Luengo; Julia Carracedo; Rafael Ramírez-Chamond; Diego Rodriguez-Puyol; Manuel Rodriguez-Puyol; Laura Calleros
Journal:  J Physiol       Date:  2014-12-18       Impact factor: 5.182

2.  Serum concentrations of p-cresyl sulfate and indoxyl sulfate, but not inflammatory markers, increase in incident peritoneal dialysis patients in parallel with loss of residual renal function.

Authors:  Liesbeth Viaene; Björn K I Meijers; Bert Bammens; Yves Vanrenterghem; Pieter Evenepoel
Journal:  Perit Dial Int       Date:  2013-10-31       Impact factor: 1.756

Review 3.  Uremic Toxins - Novel Arrhythmogenic Factor in Chronic Kidney Disease - Related Atrial Fibrillation.

Authors:  Shih-Yu Huang; Yi-Ann Chen; Shih-Ann Chen; Yi-Jen Chen; Yung-Kuo Lin
Journal:  Acta Cardiol Sin       Date:  2016-05       Impact factor: 2.672

Review 4.  Gut microbiota and chronic kidney disease: implications for novel mechanistic insights and therapeutic strategies.

Authors:  Wei Pan; Yongbo Kang
Journal:  Int Urol Nephrol       Date:  2017-08-28       Impact factor: 2.370

5.  Protein-bound uremic toxins stimulate crosstalk between leukocytes and vessel wall.

Authors:  Anneleen Pletinck; Griet Glorieux; Eva Schepers; Gerald Cohen; Bertrand Gondouin; Maria Van Landschoot; Sunny Eloot; Angelique Rops; Johan Van de Voorde; An De Vriese; Johan van der Vlag; Philippe Brunet; Wim Van Biesen; Raymond Vanholder
Journal:  J Am Soc Nephrol       Date:  2013-09-05       Impact factor: 10.121

6.  Protein-Bound Uremic Toxins and Immunity.

Authors:  Maria Teresa Rocchetti; Carmela Cosola; Elena Ranieri; Loreto Gesualdo
Journal:  Methods Mol Biol       Date:  2021

7.  NRF2 and NF-κB mRNA expression in chronic kidney disease: a focus on nondialysis patients.

Authors:  Viviane O Leal; Juliana F Saldanha; Milena B Stockler-Pinto; Ludmila F M F Cardozo; Felipe R Santos; Alex S D Albuquerque; Maurilo Leite; Denise Mafra
Journal:  Int Urol Nephrol       Date:  2015-10-22       Impact factor: 2.370

Review 8.  Colon may provide new therapeutic targets for treatment of chronic kidney disease with Chinese medicine.

Authors:  Chuan Zou; Zhao-Yu Lu; Yu-Chi Wu; Li-Hong Yang; Guo-Bin Su; Xi-Na Jie; Xu-Sheng Liu
Journal:  Chin J Integr Med       Date:  2013-01-31       Impact factor: 1.978

Review 9.  αKlotho and Chronic Kidney Disease.

Authors:  J A Neyra; M C Hu
Journal:  Vitam Horm       Date:  2016-03-24       Impact factor: 3.421

Review 10.  Cholesterol Metabolism in CKD.

Authors:  Allison B Reiss; Iryna Voloshyna; Joshua De Leon; Nobuyuki Miyawaki; Joseph Mattana
Journal:  Am J Kidney Dis       Date:  2015-09-01       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.